Immunologic Constant of Rejection (ICR) signature

Overview

A 20-gene transcriptional signature capturing T-helper-1 / cytotoxic immune activation, used to stratify tumors into ICR-high (hot), ICR-medium, and ICR-low (cold) phenotypes PMID:37202560.

Used by

• PMID:37202560 — applied to AC-ICAM (n=348 colon cancer); ICR was prognostic for OS (ICR-high vs ICR-low HR 0.54, 95% CI 0.34–0.86, P=0.0095; ICR-medium vs ICR-low HR 0.63, 95% CI 0.43–0.91, P=0.014) and outperformed CMS and MSI classifications, retaining prognostic value within the CMS4/mesenchymal subtype PMID:37202560.

Notes

• The 20-gene panel includes T-helper-1 signaling genes (IFNG, TBX21, CD8A, CD8B, IL12B, STAT1, IRF1), CXCR3/CCR5 chemokine ligands (CCL5, CXCL9, CXCL10), effector cytotoxic genes (GNLY, PRF1, GZMA, GZMB, GZMH), and immunoregulatory counter-activation genes (CD274, CTLA4, FOXP3, IDO1, PDCD1) PMID:37202560.
• Combined with a Ruminococcus bromii-driven microbiome signature into the composite mICRoScore, which identified a colon cancer subgroup with excellent survival PMID:37202560.

Sources

• PMID:37202560

This page was processed by crosslinker on 2026-04-10.